This page is part of the Making EHR Data MOre available for Research and Public Health (MedMorph) Central Cancer Registry Reporting Content IG (v1.0.0: STU1) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
Narrative
status: completed
category: Outpatient
medication: rxnorm 1790099 doxorubicin hydrochloride 20 MG per 10 ML Injection
subject: Amy Shaw
effective: 2018-04-22
Performer: Joseph Nichols
reasonReference: Condition-primary-cancer-condition-breast
authoredOn: 2018-04-12
note: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects.
Route: SNOMED 47625008 Intravenous route (qualifier value)
Dose: 105.96 mg